SUPPLEMENTARY LISTING PARTICULARS DATED 5 AUGUST 2026

HSBC Bank plc

(a company incorporated in England with registered number 14259; the liability of its members is limited)

as Issuer

HSBC Bank Middle East Limited

(a company limited by shares incorporated in the Dubai International Financial Centre)
as Issuer

HSBC Continental Europe

(a société anonyme registered in France)
as Issuer

PROGRAMME FOR THE ISSUANCE OF NOTES AND WARRANTS

This supplement (the "**Supplement**") to (i) the offering memorandum dated 2 June 2026 relating to the Programme for the Issuance of Notes and Warrants (the "**GEM Offering Memorandum**") prepared by HSBC Bank plc ("**HCIB**"), HSBC Bank Middle East Limited ("**HBME**") and HSBC Continental Europe ("**HBCE**" and, together with HCIB and HBME, the "**Issuers**" and each an "**Issuer**"); and (ii) the offering memorandum dated 22 May 2026 relating to the Programme for the Issuance of Notes and Warrants (the "**Market Access Offering Memorandum**" and, together with the GEM Offering Memorandum, the "**Offering Memoranda**" and each an "**Offering Memorandum**") prepared by HCIB each of which constitutes listing particulars for the purposes of listing ("**Listing**") on the Official List of the Irish Stock Exchange plc trading as Euronext Dublin ("**Euronext Dublin**") and trading on the Global Exchange Market of Euronext Dublin and, for the avoidance of doubt, neither of which comprises (i) a prospectus for the purposes of the Public Offers and Admissions to Trading Regulations 2024 or the United Kingdom Financial Conduct Authority ("**FCA**") Handbook Prospectus Rules: Admission to Trading on a Regulated Market sourcebook or (ii) a base prospectus for the purposes of Regulation (EU) 2017/1129 (as amended), constitutes supplementary listing particulars (pursuant to rule 3.12 of the Global Exchange Market Listing and Admission to Trading Rules for Debt Securities) for the purposes of Listing.

Terms defined in the relevant Offering Memorandum have the same meaning when used in this Supplement.

This Supplement is supplemental to, and should be read in conjunction with, the Offering Memoranda and any other supplements to the Offering Memoranda prepared by the relevant Issuer(s), in relation to their Programme for the Issuance of Notes and Warrants.

This Supplement has been approved by Euronext Dublin for the purposes of Listing.

HCIB accepts responsibility for the information contained in this Supplement relating to HCIB and Notes, Warrants and Certificates issued by it. To the best of the knowledge of HCIB (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

HBME accepts responsibility for the information contained in this Supplement relating to HBME and Notes and Warrants issued by it. To the best of the knowledge of HBME (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

HBCE accepts responsibility for the information contained in this Supplement relating to HBCE and Notes issued by it. To the best of the knowledge of HBCE (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The purpose of this Supplement is to:

- disclose that on 4 August 2026, HCIB published its unaudited consolidated interim report for the six-month period ended 30 June 2026 (the "**HCIB Unaudited Consolidated Interim Report**"). The HCIB Unaudited Consolidated Interim Report is available at https://www.hsbc.com/investors/results-and-announcements/all-reporting/subsidiaries?page=1&take=20. The HCIB Unaudited Consolidated Interim Report is hereby incorporated by reference into the Offering Memoranda;

- disclose that on 4 August 2026, HBME published its unaudited reviewed consolidated interim report for the six-month period ended 30 June 2026 (the "**HBME Unaudited Consolidated Interim Report**"). The HBME Unaudited Consolidated Interim Report is available at https://www.hsbc.com/investors/results-and-announcements/all-reporting/subsidiaries?page=1&take=20. The HBME Unaudited Consolidated Interim Report is hereby incorporated by reference into the GEM Offering Memorandum;

- disclose that on 4 August 2026, HBCE published the English version of its *1st Amendment to the Universal Registration Document and Interim Financial Report 2026* filed with the *Autorité des marchés financiers* on 4 August 2026, which includes HBCE's interim financial statements for the six-month period ended 30 June 2026 (the "**HBCE Registration Document First Amendment**"). The HBCE Registration Document First Amendment is available at https://www.hsbc.com/investors/results-and-announcements/all-reporting/subsidiaries?page=1&take=20. The HBCE Registration Document First Amendment is hereby incorporated by reference into the GEM Offering Memorandum;

- replace paragraph 2 of the '*General Information*' section of the registration document prepared by HCIB dated 15 May 2026 approved by the FCA (which is incorporated by reference into the Offering Memoranda) with the following statement:

  "There has been no significant change in the financial position or financial performance of the Issuer or the Group since 30 June 2026 nor any material adverse change in the prospects of the Issuer since 31 December 2025.";

- replace paragraph 13 of the '*General Information*' section of the GEM Offering Memorandum with the following statement:

  "There has been no significant change in the financial position of HCIB and its subsidiary undertakings since 30 June 2026 nor any material adverse change in the prospects of HCIB since 31 December 2025.";

- replace paragraph 14 of the '*General Information*' section of the GEM Offering Memorandum with the following statement:

"There has been no significant change in the financial position of HBME and its subsidiaries since 30 June 2026 nor any material adverse change in the prospects of HBME since 31 December 2025.";

- replace paragraph 15 of the '*General Information*' section of the GEM Offering Memorandum with the following statement:

  "There has been no significant change in the financial position of HBCE and its subsidiaries since 30 June 2026 nor any material adverse change in the prospects of HBCE since 31 December 2025."; and

- replace paragraph 7 of the '*General Information*' section of the Market Access Offering Memorandum with the following statement:

  "There has been no significant change in the financial position of the Issuer and its subsidiary undertakings since 30 June 2026 nor any material adverse change in the prospects of the Issuer since 31 December 2025."

To the extent that any document or information incorporated by reference itself incorporates any information by reference, either expressly or impliedly, such information will not form part of this Supplement or the relevant Offering Memorandum, except where such information or documents are stated within this Supplement as specifically being incorporated by reference or where this Supplement is specifically defined as including such information. To the extent that only certain parts of the above documents are specified to be incorporated by reference herein, the non-incorporated parts of such documents are either not relevant for investors or covered elsewhere in this Supplement or the relevant Offering Memorandum.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated into the relevant Offering Memorandum by this Supplement and (b) any other statement in or incorporated by reference in the relevant Offering Memorandum, the statements in this Supplement will prevail.

HCIB confirms that, save as disclosed in this Supplement, no significant new factor, material mistake or material inaccuracy relating to information included in the Offering Memoranda and relating to HCIB and Notes, Warrants and Certificates issued by it under the Programme has arisen or been noted, as the case may be, since the publication of the Offering Memoranda.

HBME confirms that, save as disclosed in this Supplement, no significant new factor, material mistake or material inaccuracy relating to information included in the GEM Offering Memorandum and relating to HBME and Notes and Warrants issued by it under the Programme has arisen or been noted, as the case may be, since the publication of the GEM Offering Memorandum.

HBCE confirms that, save as disclosed in this Supplement, no significant new factor, material mistake or material inaccuracy relating to information included in the GEM Offering Memorandum and relating to HBCE and Notes issued by it under the Programme has arisen or been noted, as the case may be, since the publication of the GEM Offering Memorandum.